Concord Biotech is pleased to announce the successful completion of the Russian GMP (Good Manufacturing Practice) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility located in Dholka, Gujarat.
The inspection was conducted from July 22, 2025, to July 25, 2025.
In the exchagne filings, the company shared, “We are pleased to announce the successful completion of the Russian GMP (Good Manufacturing Practice) inspection at our Active Pharmaceutical Ingredient (API) manufacturing facility located in Dholka, Gujarat. The inspection was conducted from July 22’ 2025 to July 25’ 2025.”
This achievement underscores the company’s commitment to upholding the highest standards of quality, safety, and regulatory compliance across all areas of its operations. It also reflects Concord Biotech’s continued focus on meeting the rigorous requirements of global regulatory authorities.
